Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication

Abstract excerpt

Interindividual differences in the pharmacokinetics of a number of drugs are often due to hereditary polymorphisms of drug-metabolizing enzymes. Most important is cytochrome p4502D6 (CYP2D6), also known as debrisoquine/sparteine hydroxylase. It catalyzes hydroxylation or demethylation of more than 20% of drugs metabolized in the human liver, such as neuroleptics, antidepressants, some beta-blockers and many...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Treatment and Pharmacology
• Share to Drug Transport and Resistance Mechanisms
• Share to Pharmacogenetics and Drug Metabolism